Trial Profile
A randomized phase II study of concomitant trastuzumab, bevacizumab with paclitaxel versus trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab and paclitaxel at progression as first-line treatment of patients with metastatic breast cancer with HER2-neu overexpression.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms HAT
- 17 Jun 2016 Status changed from active, no longer recruiting to completed, as per the results published in the Cancer
- 17 Jun 2016 Results published in the Cancer
- 31 Mar 2009 New trial record